Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Emergence of High-Level Cefiderocol Resistance in Carbapenem-Resistant Klebsiella pneumoniae from Bloodstream Infections in Patients with Hematologic Malignancies in China
Authors
Keywords
-
Journal
Microbiology Spectrum
Volume 10, Issue 2, Pages -
Publisher
American Society for Microbiology
Online
2022-03-25
DOI
10.1128/spectrum.00084-22
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Contribution of PER-Type and NDM-Type β-Lactamases to Cefiderocol Resistance in Acinetobacter baumannii
- (2021) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Rapid Development of Cefiderocol Resistance in Carbapenem-resistant Enterobacter cloacae During Therapy Is Associated With Heterogeneous Mutations in the Catecholate Siderophore Receptor cirA
- (2021) Sabrina Klein et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol: A Review in Serious Gram-Negative Bacterial Infections
- (2021) Yahiya Y. Syed DRUGS
- A genomic surveillance framework and genotyping tool for Klebsiella pneumoniae and its related species complex
- (2021) Margaret M. C. Lam et al. Nature Communications
- New Delhi Metallo-Beta-Lactamase Facilitates the Emergence of Cefiderocol Resistance in Enterobacter cloacae
- (2021) Dennis Nurjadi et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In Vitro Evolution of Cefiderocol Resistance in an NDM-Producing Klebsiella pneumoniae Due to Functional Loss of CirA
- (2021) Christi L. McElheny et al. Microbiology Spectrum
- The Lancet Infectious Diseases Commission on antimicrobial resistance: 6 years later
- (2020) Ramanan Laxminarayan et al. LANCET INFECTIOUS DISEASES
- Structural basis of reduced susceptibility to ceftazidime–avibactam and cefiderocol in Enterobacter cloacae due to AmpC R2 loop deletion
- (2020) Akito Kawai et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Cefiderocol: A Siderophore Cephalosporin
- (2020) Rania M. El-Lababidi et al. ANNALS OF PHARMACOTHERAPY
- Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
- (2020) Matteo Bassetti et al. LANCET INFECTIOUS DISEASES
- Cefiderocol: A Novel Siderophore Cephalosporin against Multidrug‐Resistant Gram‐Negative Pathogens
- (2020) Jacinda C. Abdul‐Mutakabbir et al. PHARMACOTHERAPY
- Reduced susceptibility mechanism to cefiderocol, a siderophore cephalosporin, among clinical isolates from a global surveillance programme (SIDERO-WT-2014)
- (2020) Naoki Kohira et al. Journal of Global Antimicrobial Resistance
- Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli
- (2019) George G. Zhanel et al. DRUGS
- NDM Metallo-β-Lactamases and Their Bacterial Producers in Health Care Settings
- (2019) Wenjing Wu et al. CLINICAL MICROBIOLOGY REVIEWS
- Epidemiology and mortality in bacterial bloodstream infections in patients with hematologic malignancies
- (2019) Duygu Mert et al. Journal of Infection in Developing Countries
- In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
- (2019) Yoshinori Yamano CLINICAL INFECTIOUS DISEASES
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
- (2018) Jesús Rodríguez-Baño et al. CLINICAL MICROBIOLOGY REVIEWS
- Ceftazidime-Avibactam: A Review in the Treatment of Serious Gram-Negative Bacterial Infections
- (2018) Matt Shirley DRUGS
- Precise and efficient genome editing in Klebsiella pneumoniae using CRISPR-Cas9 and CRISPR-assisted cytidine deaminase
- (2018) Yu Wang et al. APPLIED AND ENVIRONMENTAL MICROBIOLOGY
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Bloodstream infections caused byKlebsiella pneumoniaein onco-hematological patients: clinical impact of carbapenem resistance in a multicentre prospective survey
- (2016) Enrico Maria Trecarichi et al. AMERICAN JOURNAL OF HEMATOLOGY
- The global epidemiology of carbapenemase-producing Enterobacteriaceae
- (2016) David van Duin et al. Virulence
- TonB or not TonB: is that the question?This paper is one of a selection of papers published in a Special Issue entitled CSBMCB 53rd Annual Meeting — Membrane Proteins in Health and Disease, and has undergone the Journal’s usual peer review process.
- (2011) Karla D. Krewulak et al. Biochemistry and Cell Biology
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now